MarginsXMarginsX
Home › Markets › AURX

Nuo Therapeutics, Inc. (AURX)

AURX is quoted over the counter, not listed on an exchange. Nuo Therapeutics, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Last trade · November 11, 2026
$1.09
No trades since Nov 11, 2026; later closes repeat the last quote
1-year return
-48.3%
Market cap
$53.0M
Micro cap. From the Nov 11, 2026 last trade × 48.6M shares (10-Q cover page, Nov 12, 2026)
P/E and P/S
Net loss over the period · 10.2×
On trailing twelve months to June 30, 2026 (10-Q)

Closes: Yahoo Finance daily closes, last bar 2026-11-13.

Profile

FieldValue
TickerAURX, quoted over the counter
SEC CIK0001091596
OTC Markets tierOTCQB (price source, 2026-11-13)
SEC industry codeSurgical & Medical Instruments & Apparatus
Business addressHouston, TX
Incorporated inDE

Warning signs

Cash runway
2.5 months
$449K cash at June 30, 2026
Share count, 1 year
+1.1%
2025-10-29 to 2026-11-12 · +14.8% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
-$290K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As such, we believe that substantial doubt about our ability to continue as a going concern exists."
10-Q 2026-11-13
Cash and burn$449K cash; operating cash flow -$537K a quarter.Report 2026-06-30
Shares outstanding48,585,593 (2026-11-12); 48,077,745 a year earlier; 42,316,516 three years earlier.Cover page 2026-11-12
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorMaloneBailey, LLP, Houston, Texas, United StatesPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $10K, sold $300K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$1.8M-$278K-$236K$449KNo debt tags$5.2M10-Q 2026-08-14
Q1 2026
2026-03-31
$1.3M-$618K-$784K$264KNo debt tags$4.1M10-Q 2026-05-14
Q4 2025
2025-12-31
$1.1M-$578K-$423K$549KNo debt tags$3.3M10-K 2026-03-30
Q3 2025
2025-09-30
$1.0M-$538K-$707K$515KNo debt tags$2.6M10-Q 2025-10-30
Q2 2025
2025-06-30
$700K-$650K$262K$316KNo debt tags$2.0M10-Q 2026-08-14
Q1 2025
2025-03-31
$484K-$746K$2K$56KNo debt tags$1.6M10-Q 2026-05-14
Q4 2024
2024-12-31
$395K-$497K-$491K$284KNo debt tags$1.4M10-K 2026-03-30
Q3 2024
2024-09-30
$371K-$578K-$487K$684KNo debt tags$1.2M10-Q 2025-10-30

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32025-05-01
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-10-06
Latest proxyDEFA14A2025-10-30

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier